Citation Information :
Mishra K, Manna A, Roy RM, Roy Y, Choudhury K. Therapeutic Efficacy of Ivermectin in Novel Coronavirus Disease-2019 Patient Admitted at the Ward of a Tertiary Care Hospital: A Retrospective Study. Indian J Respir Care 2023; 12 (1):3-7.
Objective: An observational, retrospective, institution-based study to observe the pattern of ivermectin use related to patients’ characteristics. Methods: Patient data including short-term diagnosis, investigations done, and drug usage data were captured in a predesigned, structured case report form; and suspected adverse events were recorded in the standard suspected adverse drug reaction reporting form recommended by the “Central Drug Standard Control Organization,” India. The study was for a period of 7 months from August 01, 2020, to February 28, 2021. A total of 4,552 patients were recruited in this study and followed up till their discharge or death. The comparison was made between not given and given of ivermectin among patients. Results: Data were summarized by routine descriptive and statistical analysis. The mean age (years), length of stay (days) onset from hospitalization, pulse rate, systolic blood pressure (SBP), and temperature did not show significant change. However, respiratory rate was found to decrease significantly (p < 0.001), and oxygen saturation (SpO2) was found to increase significantly (p < 0.001) in the ivermectin-treated group. It was also observed that a positive correlation with a highly significant value (p < 0.000) between age (years), length of stay (days) onset from, pulse rate, SBP, and temperature and ivermectin usage while a negative correlation with highly significant value (p < 0.000) between SpO2 and ivermectin usage was obtained. Conclusion: As per the studied parameters, a significant correlation was observed in combinations of the treated and untreated groups. Further research suggested the dose-dependent efficacy of ivermectin usage in the novel coronavirus disease-2019 patients.
Johns Hopkins University of Medicine COVID-19. COVID-19 Dashboard by the Center for Systems Science and. Engineering (CSSE) at Johns Hopkins University. 2020. Available from: https://coronavirus.jhu.edu/map.html. [Last accessed on 2021 Dec 25].
Ahmed S, Karim MM, Ross AG, et al. A five–day course of Ivermectin for the treatment of COVID–19 may reduce the duration of illness. Int J Infect Dis 2021;103:214–216.
Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020;178:104787.
Crump A, Ōmura S. Ivermectin, “wonder drug” from Japan: The human use perspective: Proc Jpn Acad Ser B Phys Biol Sci 2011;87:13–28.
Kory P, Meduri GU, Varon J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther 2021;28:e299–318.
Mastrangelo E, Pezzullo M, De Burghgraeve T, et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: New prospects for an old drug. J Antimicrob Chemother 2012;67:1884–1894.
Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J 2012;443:851–856.
Tay MY, Fraser JE, Chan WK, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res 2013;99:301–306.
Götz V, Magar L, Dornfeld D, et al. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci Rep 2016;6:23138.
Varghese FS, Kaukinen P, Gläsker S, et al. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Res 2016;126:117–124.
Atkinson SC, Audsley MD, Lieu KG, et al. Recognition by host nuclear transport proteins drives disorder-to-order transition in Hendra virus V. Sci Rep 2018;8:358.
Lv C, Liu W, Wang B, et al. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo. Antiviral Res 2018;159:55–62.
King CR, Tessier TM, Dodge MJ, et al. Inhibition of human adenovirus replication by the importin α/β1 nuclear import inhibitor ivermectin. J Virol 2020;94:e00710–20.
Yang SN, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res 2020;177:104760.
Bray M, Rayner C, Noël F, et al. Ivermectin and COVID-19: A report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses. Antiviral Res 2020;178:104805.
Schmith VD, Zhou JJ, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther 2020;108:762–5.
Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high–dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. EClinical Medicine 2021;37:100959.
Lim SC, Hor CP, Tay KH, et al. Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: The I-Tech randomized clinical trial. JAMA Intern Med 2022;182:426–35.
Vallejos J, Zoni R, Bangher M, et al. Ivermectin to prevent hospitalizations in patients with COVID-19(IVERCOR-COVID-19) a randomized, double-blind, placebo-controlled trial. BMC Infect Dis 2021;21:635.
Okumuş N, Demirtürk N, Çetinkaya RA, et al. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infect Dis 2021;21:411.
Schmith VD, Zhou JJ, Lohmer LR. The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19. Clin Pharmacol Ther 2020;108:762–5.
Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: Antiviral levels are not likely attainable with known dosing regimens. Biotechnol Biotechnol Equip 2020;34:469–74.
